Bavituximab

Product NameBavituximab
CAS648904-28-3
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Uses

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].

in vivo

Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo^[2].

Animal Model:	Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors^[2]
Dosage:	100 μg/mouse (Bavituximab/β2GP1)
Administration:	Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)
Result:	Traced phosphatidylserine exposure in vivo in mice with tumors.

References

[1] Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. DOI:10.1016/j.lungcan.2014.08.010
[2] Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. DOI:10.1245/s10434-016-5107-5